Our Services
Medical Information
Helpful Resources
Published on: 10/26/2026
Cymbalta (duloxetine) is linked to several difficult side effects, including nausea, insomnia, heavy sweating, fatigue, sexual dysfunction, appetite changes, and in some people raised blood pressure or liver strain. Stopping suddenly can trigger discontinuation symptoms such as "brain zaps," dizziness, irritability, crying spells, and flu-like aches, which is why tapering should follow a plan set with a prescriber. Dose, length of use, and individual sensitivity all change how hard the process feels, so there are several important factors to consider before making any change, explained below.
Because withdrawal effects and medication side effects can look a lot like a return of depression, anxiety, or an unrelated health issue, sorting out what you are actually feeling is the first step toward a safe next move. Take a free, instant, online symptom check to clarify your symptoms and get guidance on how urgently to talk with a clinician.
Last reviewed for medical accuracy: 10/22/2026
Cymbalta (duloxetine) is a widely prescribed antidepressant and nerve‐pain medication. Like all medications, it carries potential side effects—some mild and temporary, others rare but serious. Understanding what the worst side effects of Cymbalta can be, and why you need a careful taper plan to stop, helps you stay informed and safe.
While many people tolerate Cymbalta well, a small number experience severe reactions. Below is a breakdown from more common to rare but dangerous:
These are more common but can still significantly impact day-to-day life:
Many of these improve over weeks. Talk with your doctor if they persist or interfere with activities.
Abruptly stopping Cymbalta often leads to discontinuation syndrome, which can feel alarming:
These usually begin within a few days of stopping and can last weeks or longer if not managed properly.
A well-structured taper decreases the intensity of discontinuation symptoms and helps prevent relapse of depression or anxiety.
Speak to a doctor or call emergency services if you experience any of the following:
For any life-threatening or serious concerns, always prioritize professional medical care.
Cymbalta can be an effective tool against depression, anxiety, and nerve pain—but like all medications, it carries risks. By knowing what the worst side effects of Cymbalta are, and why stopping without a plan can backfire, you position yourself to make safer choices.
Before making any changes:
If you ever feel overwhelmed or notice alarming symptoms, speak to a doctor right away. Your safety and well-being come first.
(References)
* Boehmerle W, Huehnchen P, Endres M. [Chemotherapy-induced neuropathy]. Nervenarzt. 2015 Feb;86(2):156-60. doi: 10.1007/s00115-014-4126-3. PMID: 25586233.
* Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother. 2016;16(2):131-44. doi: 10.1586/14737175.2016.1135735. Epub 2016 Jan 14. PMID: 26693882.
* Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. PMID: 30016772.
* Drugs for anxiety disorders. Med Lett Drugs Ther. 2019 Aug 12;61(1578):121-126. PMID: 31386647.
* Nonopioid drugs for pain. Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40. PMID: 35231019.
* Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. PMID: 36253442; PMCID: PMC9812779.
* Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA, Phillippo D, Pincus T. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023 May 10;5(5):CD014682. doi: 10.1002/14651858.CD014682.pub2. Epub 2023 May 10. PMID: 37160297; PMCID: PMC10169288.
* Drugs for migraine. Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96. doi: 10.58347/tml.2023.1678a. PMID: 37266987.
* Migliorini F, Maffulli N, Eschweiler J, Baroncini A, Bell A, Colarossi G. Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis. J Orthop Surg Res. 2023 Jul 17;18(1):504. doi: 10.1186/s13018-023-03995-z. Epub 2023 Jul 17. PMID: 37461044; PMCID: PMC10351165.
* Bragg S, Marrison ST, Haley S. Diabetic Peripheral Neuropathy: Prevention and Treatment. Am Fam Physician. 2024 Mar;109(3):226-232. PMID: 38574212.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.